Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells.

Abstract

PIM1 kinase and MYC are commonly co-expressed in human prostate cancer and synergize to induce rapidly progressing prostate cancer in mouse models. Deficiency of the Pim kinase genes is well tolerated in vivo, suggesting that PIM1 inhibition might offer an attractive therapeutic modality for prostate cancer, particularly for MYC-expressing tumors. Here we examine the molecular consequences of Pim1 and MYC overexpression in the prostate as well as the effects of depleting Pim1 in prostate carcinoma cells with high levels of MYC. Overexpression of Pim1 in the mouse prostate induces several pro-tumorigenic genetic programs including cell cycle genes and Myc-regulated genes before the induction of any discernible pathology. Pim1 depletion by RNA interference in mouse and human prostate cancer cells decreased cellular proliferation, survival, Erk signaling and tumorigenicity even when MYC levels were not significantly altered. These results indicate that PIM1 may be necessary to maintain tumorigenicity, and further support efforts aimed at developing PIM1 inhibitors for prostate cancer therapy.

• Authors: J Wang, P D Anderson, W Luo, D Gius, M Roh, S A Abdulkadir
• Journal: Oncogene (Oncogene) Vol. 31 Issue 14 Pg. 1794-803 (Apr 05 2012) ISSN: 1476-5594 [Electronic] England
• PMID: 21860423 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Proto-Oncogene Proteins c-myc
• Proto-Oncogene Proteins c-pim-1

Topics

• Animals
• Cell Line, Tumor
• Gene Expression Regulation, Neoplastic
• Gene Knockdown Techniques
• Humans
• MAP Kinase Signaling System
• Male
• Mice
• Prostatic Neoplasms (genetics, metabolism, pathology)
• Proto-Oncogene Proteins c-myc (genetics)
• Proto-Oncogene Proteins c-pim-1 (genetics, physiology)
• Up-Regulation